PRESS
Oney Studio / Blog / Press release
Google Ads Policy for Peptide Brands: The Complete 2026 Guide
Oney Studio distributed this press release to explain how peptide brands can run Google Ads in 2026 without losing their accounts. This page is a summary and a record of where the release was distributed. The full, regularly updated guide is on our blog.
What the release covers
- The category is enforced, not banned. Peptide brands can run Google Ads, but the result depends on how the account is set up, how the copy is written and how the campaigns are structured before any budget is spent.
- Why accounts get flagged. Compound names in headlines, mechanism-of-action language, landing pages that fail automated scanning, and early policy violations that build a record on the account.
- A phased cold-start approach. Compliance review before launch, manual CPC with branded and high-intent campaigns first, expansion once there is conversion data, and Performance Max last.
- What to do if an account is already flagged. Audit everything before reactivating, avoid repeated appeals on an unchanged issue, and fix structural problems, not only individual ads.
- FAQs on Shopping, Performance Max, research-use disclaimers and Google versus Meta Ads.
Where it was distributed
The release was published on the ABNewswire press release network and syndicated to local news, finance and industry sites, including the press release section of AP News.
These are paid press release distributions. They are labelled as such by the publishers, and the newsrooms were not involved in their creation. They are not editorial coverage.
Work with us
If your peptide or supplement brand is launching Google Ads, or has been flagged or suspended, we'll review your products, ads and landing pages and tell you what can run. Book a free 30-minute policy audit.
This release reflects Oney Studio's operating experience and is not legal advice. Advertising requirements vary by jurisdiction, product and platform policy changes. Check Google's current policies before acting.